Brand Name

Olumiant

Generic Name
Baricitinib
View Brand Information
FDA approval date: May 31, 2018
Classification: Janus Kinase Inhibitor
Form: Tablet

What is Olumiant (Baricitinib)?

OLUMIANT ® is a Janus kinase inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Fol...

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Who is this study for: Child to young adult patients with Juvenile Idiopathic Arthritis
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3

Summary: The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Who is this study for: Child to young adult patients with Juvenile Idiopathic Arthritis
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3

Summary: The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.

View All Clinical Trials

Related Latest Advances

Deuruxolitinib for Alopecia Areata.
Deuruxolitinib for Alopecia Areata.
Journal: Skin therapy letter
Published: January 20, 2026
Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan.
Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan.
Journal: Journal of medical economics
Published: January 20, 2026
T-cell-predominant inflammation in livedoid vasculopathy and response to baricitinib.
T-cell-predominant inflammation in livedoid vasculopathy and response to baricitinib.
Journal: JAAD international
Published: January 19, 2026
View All Latest Advances

Brand Information

Olumiant (baricitinib)
1CONTRAINDICATIONS
None.
2ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
  • Serious Infections
  • Mortality
  • Malignancy and Lymphoproliferative Disorders
  • Major Adverse Cardiovascular Events
  • Thrombosis
  • Hypersensitivity
  • Gastrointestinal Perforations
  • Laboratory Abnormalities
2.1Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.
2.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of OLUMIANT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
Immune System Disorders: Drug hypersensitivity (events such as rash, urticaria, and angioedema have been reported) [see Warnings and Precautions (.
3OVERDOSAGE
Single doses up to 40 mg and multiple doses of up to 20 mg daily for 10 days have been administered in clinical trials without dose-limiting toxicity. Pharmacokinetic data of a single dose of 40 mg in healthy volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 24 hours.
In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
4DESCRIPTION
OLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7
Structural Formula
OLUMIANT tablets contain a recessed area on each face of the tablet surface and are available for oral administration as debossed, film-coated tablets. The 1 mg tablet is very light pink, round, debossed with “Lilly” on one side and “1” on the other. The 2 mg tablet is light pink, oblong, debossed with “Lilly” on one side and “2” on the other. The 4 mg tablet is medium pink, round, debossed with “Lilly” on one side and “4” on the other.
Each tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
5PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (
6PACKAGE LABEL – OLUMIANT 2 mg 30ct Bottle
Rx Only
Always Dispense with Medication Guide
NDC 0002-4182-30
Olumiant
(baricitinib) tablets
2 mg
30 tablets
Lilly
PACKAGE LABEL – OLUMIANT 2 mg 30ct Bottle
7PACKAGE LABEL – OLUMIANT 1 mg 30ct Bottle
Rx Only
Always Dispense with Medication Guide
NDC 0002-4732-30
Olumiant
(baricitinib) tablets
1 mg
30 tablets
Lilly
PACKAGE LABEL – OLUMIANT 1 mg 30ct Bottle
8PACKAGE LABEL – OLUMIANT 4 mg 30ct Bottle
Rx Only
Always Dispense with Medication Guide
NDC 0002-4479-30
Olumiant
(baricitinib) tablets
4 mg
30 tablets
Lilly
PACKAGE LABEL – OLUMIANT 4 mg 30ct Bottle